Date:11/8/2012

3.  Additionally, this action will likely assist in expanding healthcare professional and patient interest in film formulations, all of which potentially benefit BNX.  Given the merits of the BEMA drug delivery technology, we believe BNX is particularly well positioned to garner significant market share from Suboxone film.  Our original peak annual sales projection for BNX was near $300 million.  However, based on the apparent removal of the Suboxone tablets, we now anticipate potential BNX peak sales could be in excess of $300 million.  As the events relating to Suboxone unfold and are confirmed, we will be able to better quantify the upside potential this presents for BNX.

Additionally, Reckitt Benckiser issued a Citizens Petition to request that the FDA require all manufacturers of buprenorphine-containing products for the treatment of opioid dependence to implement public health safeguards including child-resistant, unit-dose packaging to reduce the risk of pediatric exposure.  Should the Citizens Petition be upheld by FDA, the entry of generic Suboxone tablets could be further delayed beyond the first half of 2013, creating additional potential upside opportunity for BNX.

• ONSOLIS/BREAKYL.  BDSI announced the commercial launch of BREAKYL (fentanyl buccal film) in the European Union.  BREAKYL is the brand name in the E.U. of BDSI's FDA approved product ONSOLIS.  BDSI's commercial partner for BREAKYL in the E.U. is Meda.  Under the terms of its E.U. agreement with Meda, BDSI received a final milestone payment in October 2012 of $2.5 million, which will be reflected in BDSI's fourth quarter financials.  BDSI will also receive a royalty on net sales of BREAKYL in the E.U.
  
  In the U.S., as previously announced, the re-launch timing of ONSOLIS will be determined once we reach agreement with the FDA over our resolution of certain appearance or
  '/>"/>

SOURCE BioDelivery Sciences International, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
2. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
4. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
5. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
6. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board